2. Anticipated concomitant immunosuppressive therapy (excluding non- systemic inhaled, topical skin and/or eye drop- containing corticosteroids). 3. Any concurrent condition requiring the continued use of systemic steroids (>10 mg prednisone or equivalent per day) or the use of immunosuppressive agents. All other corticosteroids must be discontinued at least 4 weeks prior first dose of study treatment. 4. Known history of hepatitis B or C with active viral replication. 5. Administration of any vaccine within 6 weeks of first dose of study treatment . 6. Tattoos, scars, or active lesions/rashes within 2 cm of the intended site of injection or if there is implanted metal within the same limb. Any device implanted in the chest (e.g., cardiac pacemaker or defibrillator) excludes the use of the deltoid muscle on the same side of the body. 7. Participation in a nother interventional clinical trial within 30 days before receiving first dose of study treatment. However, the subject may participate in observational studies.